SCHEMBL4391375

SCHEMBL4391375

CC(N)=C(C)C(=O)c1nccs1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
RBBP9 O75884 5/20 0.43
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 3/20 0.41
CYP2C19 P33261 3/20 0.41
CASP3 P42574 3/20 0.41
SENP8 Q96LD8 3/20 0.41
SENP7 Q9BQF6 3/20 0.41
SENP6 Q9GZR1 3/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PLA2G7 Q13093 1/20 0.36
HSPA9 P38646 1/20 0.36
PLA2G4A P47712 2/20 0.36
TSHR P16473 1/20 0.35
NOS1 P29475 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTT P42858 1/20 0.35
CES1 P23141 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5609781 0.80 ALDH1A1 (0.57) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL5609136 0.80 ALDH1A1 (0.69) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL28027939 0.80 ALDH1A1 (0.67) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL12801063 0.77 ALDH1A1 (0.64) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL14152809 0.77 ALDH1A1 (0.64) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL158422 0.76
SCHEMBL247631 0.76
SCHEMBL28219561 0.76 ALDH1A1 (0.68) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL10831806 0.76 ALDH1A1 (0.52) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19
SCHEMBL17844700 0.74 ALDH1A1 (0.55) ALDH1A1RBBP9CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 ALDH1A1 1920/4885RBBP9 1727/4885CYP1A2 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.